Every material Form 8-K BIOMERICA INC has filed with the SEC since June 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Biomerica director David Moatazedi told the board on October 12, 2026 that he will not stand for re-election at the company's 2026 Annual Meeting of Stockholders, scheduled for December 11, 2026. The company said the decision was not the result of any dispute or disagreement with the company or the board. Moatazedi has served on the board since December 2022 and chairs the Compensation Committee.
Moatazedi informed the board on October 12, 2026 of his decision not to seek re-election
The 2026 Annual Meeting of Stockholders is set for December 11, 2026
Moatazedi chairs the Compensation Committee and also serves on the Nominating and Corporate Governance and Audit Committees
The filing states the departure was not due to any dispute or disagreement with the company or the board
Biomerica agreed on August 20, 2026 to sell 1,393,705 common shares at $1.60 each to institutional and individual investors, including B. Riley Principal Capital and some directors and executive officers, for gross proceeds of about $2.23 million; the deal closed August 26, 2026. The filing also gives B. Riley purchasers a board designation right while they hold at least 10% of voting power, and requires registration of the resale of the shares, with liquidated damages if deadlines are missed.
1,393,705 shares sold at $1.60 per share, about $2.23 million gross proceeds
Closing occurred August 26, 2026; agreement dated August 20, 2026
B. Riley purchasers may designate one board representative while holding at least 10% of voting power
Directors and certain officers face 180-day lock-up; company must file resale registration within 30 days of closing
Biomerica agreed on May 29, 2026 to sell 78,750 shares of Diagnosis S.A., about 6% of that Polish company, for $500,000 to buyers affiliated with CEO Zackary Irani. The buyers paid upfront in exchange for a secured 12-month note at 8% interest, pending transfer of the shares, which is expected to close within thirty days subject to Polish regulatory approvals.
Shares sold: 78,750 shares of Diagnosis S.A., about 6% of issued and outstanding shares
Purchase price: $500,000, paid by buyers in exchange for a secured promissory note
Note terms: 8% annual interest, matures 12 months from May 29, 2026, secured by a lien on the shares
Closing conditions, including Polish regulatory approvals, expected to be met within thirty days of May 29, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIOMERICA INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →